A brief move into positive territory by Sarepta Therapeutics (SRPT -2.7%) midday might have been...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

A brief move into positive territory by Sarepta Therapeutics (SRPT -2.7%) midday might have been the result of comments from Wedbush (Outperform) analyst Christopher Marai who says progress on FDA approval for the company's Duchenne muscular dystrophy drug Eteplirsen is "encouraging."